Product Information
MIDODRINE HCL 5 MG TABLET is a generic product labeled by Xiromed LLC, priced at $0.1113 per EA under NDC 70700015801. Its NADAC has been published 299 times since Jan 13, 2021.
FDA first approved this application on Oct 1, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Xiromed LLCNDC
70700015801
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MIDODRINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA207849FDA Approved
10/1/2020
TE Code
AB
On Market Since
10/15/2020
Pharmacological Classes
Price Statistics
The NADAC for MIDODRINE HCL 5 MG TABLET has been published 299 times since Jan 13, 2021, and over the history we have for it it has declined 68.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1113 per EA |
|---|---|
| All-time high | $0.3736 (Apr 14, 2021) |
| All-time low | $0.1084 (Feb 18, 2026) |
| 52-week high | $0.1148 |
| 52-week low | $0.1084 |
| Median price | $0.1800 |
| Average price | $0.2017 |
| Largest weekly change | +38.5% (Aug 21, 2024) |
| Weeks tracked | 299 |
| Tracking since | Jan 13, 2021 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Xiromed LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
midodrine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
alpha-Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MIDODRINE HCL 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MIDODRINE HCL 5 MG TABLET, manufactured by Xiromed LLC, is $0.1113 per EA (NDC 70700015801), effective Sep 30, 2026.
How has the price of MIDODRINE HCL 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for MIDODRINE HCL 5 MG TABLET has declined 68.7%. It has been tracked across 299 weekly CMS publications since Jan 13, 2021.
What are the highest and lowest recorded NADAC prices for MIDODRINE HCL 5 MG TABLET?
Since Jan 13, 2021, the NADAC for MIDODRINE HCL 5 MG TABLET has ranged from a low of $0.1084 (Feb 18, 2026) to a high of $0.3736 (Apr 14, 2021), with a median of $0.1800 per EA.
Are there cheaper alternatives to MIDODRINE HCL 5 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MIDODRINE HCL 5 MG TABLET, is $0.1084 per EA — about 3% below MIDODRINE HCL 5 MG TABLET.
Who manufactures MIDODRINE HCL 5 MG TABLET?
MIDODRINE HCL 5 MG TABLET (NDC 70700015801) is labeled by Xiromed LLC, and CMS classifies it as a generic product.